title: A Cost-Effectiveness Analysis of EGFR-TK Mutation Status-Guided 1st- and 2nd-Line Treatment of Stage III/IV Non-Small Cell Lung Cancer in the UK.
authors.affiliation: Covance Inc., London, UK.
authors.forename: K
authors.initials: K
authors.lastname: Patel
authors.affiliation: Covance Inc., London, UK.
authors.forename: C
authors.initials: C
authors.lastname: Montouchet
authors.affiliation: Covance Inc., London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Cheynel
authors.affiliation: Covance Inc., London, UK.
authors.forename: L
authors.initials: L
authors.lastname: Ruff